Skip to main content
Top
Published in: Journal of General Internal Medicine 9/2016

01-09-2016 | Original Research

At-Home Versus In-Clinic INR Monitoring: A Cost–Utility Analysis from The Home INR Study (THINRS)

Authors: Ciaran S. Phibbs, PhD, Sean R. Love, Alan K. Jacobson, MD, Robert Edson, MA, Pon Su, MS, Lauren Uyeda, MA, David B. Matchar, MD, writing for the THINRS Executive Committee and Site Investigators

Published in: Journal of General Internal Medicine | Issue 9/2016

Login to get access

ABSTRACT

Background

Effective management of patients using warfarin is resource-intensive, requiring frequent in-clinic testing of the international normalized ratio (INR). Patient self-testing (PST) using portable at-home INR monitoring devices has emerged as a convenient alternative. As revealed by The Home INR Study (THINRS), event rates for PST were not significantly different from those for in-clinic high-quality anticoagulation management (HQACM), and a cumulative gain in quality of life was observed for patients undergoing PST.

Objective

To perform a cost–utility analysis of weekly PST versus monthly HQACM and to examine the sensitivity of these results to testing frequency.

Patients/Interventions

In this study, 2922 patients taking warfarin for atrial fibrillation or mechanical heart valve, and who demonstrated PST competence, were randomized to either weekly PST (n = 1465) or monthly in-clinic testing (n = 1457). In a sub-study, 234 additional patients were randomized to PST once every 4 weeks (n = 116) or PST twice weekly (n = 118). The endpoints were quality of life (measured by the Health Utilities Index), health care utilization, and costs over 2 years of follow-up.

Results

PST and HQACM participants were similar with regard to gender, age, and CHADS2 score. The total cost per patient over 2 years of follow-up was $32,484 for HQACM and $33,460 for weekly PST, representing a difference of $976. The incremental cost per quality-adjusted life year gained with PST once weekly was $5566 (95 % CI, −$11,490 to $25,142). The incremental cost-effectiveness ratio (ICER) was sensitive to testing frequency: weekly PST dominated PST twice weekly and once every 4 weeks. Compared to HQACM, weekly PST was associated with statistically significant and clinically meaningful improvements in quality of life. The ICER for weekly PST versus HQACM was well within accepted standards for cost-effectiveness, and was preferred over more or less frequent PST. These results were robust to sensitivity analyses of key assumptions.

Conclusion

Weekly PST is a cost-effective alternative to monthly HQACM and a preferred testing frequency compared to twice weekly or monthly PST.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S–198S.CrossRefPubMed Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S–198S.CrossRefPubMed
2.
go back to reference Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157:796–807.CrossRefPubMed Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157:796–807.CrossRefPubMed
3.
go back to reference Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113:42–51.CrossRefPubMed Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113:42–51.CrossRefPubMed
4.
go back to reference Matchar DB, Samsa GP, Cohen SJ, Oddone EZ. Community impact of anticoagulation services: rationale and design of the Managing Anticoagulation Services Trial (MAST). J Thromb Thrombolysis. 2000;9(Suppl 1):S7–11.CrossRefPubMed Matchar DB, Samsa GP, Cohen SJ, Oddone EZ. Community impact of anticoagulation services: rationale and design of the Managing Anticoagulation Services Trial (MAST). J Thromb Thrombolysis. 2000;9(Suppl 1):S7–11.CrossRefPubMed
5.
go back to reference Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641–1647.CrossRefPubMed Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641–1647.CrossRefPubMed
6.
go back to reference Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2010:CD003839. Garcia-Alamino JM, Ward AM, Alonso-Coello P, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2010:CD003839.
7.
go back to reference Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363:1608–1620.CrossRefPubMed Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363:1608–1620.CrossRefPubMed
8.
go back to reference Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol. 2007;118:54–61.CrossRefPubMed Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol. 2007;118:54–61.CrossRefPubMed
9.
go back to reference Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379:322–334.CrossRefPubMed Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379:322–334.CrossRefPubMed
10.
go back to reference Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000;9:283–292.CrossRefPubMed Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000;9:283–292.CrossRefPubMed
11.
go back to reference Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–184S.CrossRefPubMedPubMedCentral Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–184S.CrossRefPubMedPubMedCentral
12.
go back to reference Horseman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): Concepts, Measurement Properties and Applications. Health and Quality of Life Outcomes (electronic journal). 2003;1. Horseman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): Concepts, Measurement Properties and Applications. Health and Quality of Life Outcomes (electronic journal). 2003;1.
13.
go back to reference Matchar DB, Love SR, Jacobson AK, et al. The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis. 2015;40:17–25.CrossRefPubMed Matchar DB, Love SR, Jacobson AK, et al. The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis. 2015;40:17–25.CrossRefPubMed
14.
go back to reference Matchar DB, Jacobson AK, Edson RG, et al. The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481-The Home INR Study (THINRS). J Thromb Thrombolysis. 2005;19:163–172. Matchar DB, Jacobson AK, Edson RG, et al. The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481-The Home INR Study (THINRS). J Thromb Thrombolysis. 2005;19:163–172.
15.
go back to reference Dolor RJ, Ruybalid RL, Uyeda L, et al. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). J Thromb Thrombolysis. 2010;30:263–275.CrossRefPubMed Dolor RJ, Ruybalid RL, Uyeda L, et al. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). J Thromb Thrombolysis. 2010;30:263–275.CrossRefPubMed
18.
go back to reference Samsa G, Matchar DB, Dolor RJ, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes. 2004;2:22.CrossRefPubMedPubMedCentral Samsa G, Matchar DB, Dolor RJ, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes. 2004;2:22.CrossRefPubMedPubMedCentral
19.
go back to reference Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2002. Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2002.
20.
go back to reference Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc. 1996;276:1253–1258.CrossRef Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc. 1996;276:1253–1258.CrossRef
21.
go back to reference Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. J Am Med Assoc. 1996;276:1339–1341.CrossRef Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. J Am Med Assoc. 1996;276:1339–1341.CrossRef
22.
go back to reference Glick H. Web Resources for Economic Evaluation in Clinical Trials. 2012; http://www.uphs.upenn.edu/dgimhsr/eeinct.htm. Accessed 3 February 2016. Glick H. Web Resources for Economic Evaluation in Clinical Trials. 2012; http://​www.​uphs.​upenn.​edu/​dgimhsr/​eeinct.​htm.​ Accessed 3 February 2016.
23.
go back to reference Glick H, Doshi J, Sonnad S, Polsky D. Economic evaluation in clinical trials. Oxford, UK: Oxford University Press; 2007. Glick H, Doshi J, Sonnad S, Polsky D. Economic evaluation in clinical trials. Oxford, UK: Oxford University Press; 2007.
24.
go back to reference Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med. 2001;33:344–349.CrossRefPubMed Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med. 2001;33:344–349.CrossRefPubMed
25.
go back to reference Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics. 1999;15:141–155.CrossRefPubMed Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics. 1999;15:141–155.CrossRefPubMed
28.
go back to reference Holder KA. The Educational Attainment of Veterans: 2007. 2009; https://www.census.gov/hhes/veterans/files/veteranseducation.pdf. Accessed 3 February 2016. Holder KA. The Educational Attainment of Veterans: 2007. 2009; https://​www.​census.​gov/​hhes/​veterans/​files/​veteranseducatio​n.​pdf.​ Accessed 3 February 2016.
29.
go back to reference Turakhia MP, Hoang DD, Xu X, et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. Am Heart J. 2013;165:93–101.CrossRefPubMed Turakhia MP, Hoang DD, Xu X, et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. Am Heart J. 2013;165:93–101.CrossRefPubMed
Metadata
Title
At-Home Versus In-Clinic INR Monitoring: A Cost–Utility Analysis from The Home INR Study (THINRS)
Authors
Ciaran S. Phibbs, PhD
Sean R. Love
Alan K. Jacobson, MD
Robert Edson, MA
Pon Su, MS
Lauren Uyeda, MA
David B. Matchar, MD
writing for the THINRS Executive Committee and Site Investigators
Publication date
01-09-2016
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 9/2016
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-016-3700-8

Other articles of this Issue 9/2016

Journal of General Internal Medicine 9/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine